Efavaleukin alfa
- Generic Name
- Efavaleukin alfa
- Drug Type
- Biotech
- CAS Number
- 2049067-94-7
- Unique Ingredient Identifier
- YNH9K62UXU
- Background
Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker. It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants
- Conditions
- Chronic Graft-versus-Host Disease (cGVHD)
- Interventions
- Other: Placebo
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 18
- Registration Number
- NCT05885451
- Locations
- 🇦🇺
Research Site, Randwick, New South Wales, Australia
A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants
- Conditions
- Chronic Graft-versus-host Disease (cGVHD)
- Interventions
- Other: Placebo
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 64
- Registration Number
- NCT05873907
- Locations
- 🇺🇸
Research Site, Aventura, Florida, United States
Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 92
- Registration Number
- NCT05672199
- Locations
- 🇺🇸
Santa Maria Gastroenterology Medical Group, Santa Maria, California, United States
🇺🇸Indian Health Service Health Research, Kissimmee, Florida, United States
🇺🇸University of Kansas Medical Center, Kansas City, Kansas, United States
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 224
- Registration Number
- NCT04987307
- Locations
- 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸Birmingham Digestive Health Research, LLC, Homewood, Alabama, United States
🇺🇸Arizona Health Research, Mesa, Arizona, United States
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT04987333
- Locations
- 🇬🇧
Labcorp Clinical Research Unit - Leeds, Leeds, LDS, United Kingdom
Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 168
- Registration Number
- NCT04680637
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Toulouse - Hopital Rangueil, Toulouse Cedex 9, France
🇯🇵Center Hospital of the National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
🇰🇷Daegu Catholic Universtiy Medcial Center, Daegu, Korea, Republic of
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT03451422
- Locations
- 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇵🇱Clinical Research Center Spzoo Medic-R Spolka Komandytowa, Poznan, Poland
Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
- Conditions
- Chronic Graft Versus Host Disease cGVHD
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT03422627
- Locations
- 🇺🇸
Texas Oncology Baylor, Dallas, Texas, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇫🇷Hôpital Saint Louis, Paris Cedex 10, France
Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2018-01-25
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT03410056
- Locations
- 🇪🇸
Research Site, A Coruña, Galicia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.